mTOR inhibitors are the first available therapy targeting the pathogenic mechanism of TSC.[19] However, not all patients with TSC‐related epilepsy respond to mTOR inhibitors.[3, 8] More than 60% of patients fail to achieve seizure freedom, experiencing only partial reductions in seizure frequency, which are very similar to the classical anti‐seizure medications.[20, 21] Thus, the phenotypes of TSC‐related epilepsy should not be exclusively attributed to mTORC1 hyperactivity, and current understanding of the molecular mechanism in TSC‐related epilepsy remains incomplete.[8]. This evidence concerns the gene MTOR and tuberous sclerosis.